3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
17
Surveys and Questionnaires
12
Specimen Handling
11
Docetaxel
11
Nivolumab
9
Interviews as Topic
9
Standard of Care
8
Gemcitabine
8
Early Intervention, Educational
8
olaparib
7
enzalutamide
7
Magnetic Resonance Spectroscopy
7
Psychiatric Rehabilitation
6
Paclitaxel
6
durvalumab
5
Trastuzumab
5
Radiotherapy
5
Ipilimumab
5
Carboplatin
5
Bevacizumab
5
pertuzumab
4
palbociclib
4
cabozantinib
4
atezolizumab
4
abiraterone
4
Therapeutics
4
Taxes
4
Oxaliplatin
4
Methods
4
Immunoglobulin G
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Interleukin-15
×
Gastrointestinal
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled